首页> 外文期刊>Small >Synergistic targeting of cancer and associated angiogenesis using triple-targeted dual-drug silica nanoformulations for theragnostics
【24h】

Synergistic targeting of cancer and associated angiogenesis using triple-targeted dual-drug silica nanoformulations for theragnostics

机译:使用三靶点双药物二氧化硅纳米制剂对肿瘤治疗进行协同靶向治疗癌症和相关血管生成

获取原文
获取原文并翻译 | 示例
           

摘要

The targeting and therapeutic efficacy of dye- and dual-drug-loaded silica nanoparticles, functionalized with triple targeting ligands specific towards cancer and neoangiogenesis simultaneously, are discussed. This synergized, high-precision, multitarget concept culminates in an elevated uptake of nanoparticles by cancer and angiogenic cells with amplified proficiency, thereby imparting superior therapeutic efficacy against breast cancer cells and completely disabling the migration and angiogenic sprouting ability of activated endothelial cells. The exceptional multimodal efficiency achieved by this single therapeutic nanoformulation holds promise for the synergistic targeting and treatment of the yet elusive cancer and its related angiogenesis in a single, lethal shot.
机译:讨论了载有染料和双药的二氧化硅纳米粒子的靶向和治疗功效,该纳米粒子同时具有针对癌症和新血管生成的三重靶向配体功能化。这种协同的,高精度的多目标概念最终导致癌细胞和血管生成细胞对纳米颗粒的摄取增加,并具有较高的熟练度,从而赋予乳腺癌细胞以优异的治疗效果,并完全禁用活化的内皮细胞的迁移和血管生成发芽能力。通过这种单一的治疗性纳米制剂实现的非凡的多峰效率,有望在一次致命的注射中协同靶向和治疗尚难捉摸的癌症及其相关的血管生成。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号